Amneal Pharmaceuticals is recalling 2,460 cartons of Isotretinoin Capsules, USP 10 mg (a medication used for severe acne). The recall was initiated because routine testing found tretinoin levels slightly above the allowed limit, indicating a failure in the drug's stability and impurity specifications. While this is a low-risk recall, patients using medication from the affected batches may not be receiving the exact formulation intended by the manufacturer. These products were distributed to retailers and wholesalers across the United States in late 2019.
The presence of impurities or degradation products above the established limits can potentially affect the medication's safety or effectiveness. While no injuries or adverse events have been reported, tretinoin levels exceeding specifications mean the drug does not meet the quality standards required for patient use.
Contact your healthcare provider or pharmacist for guidance. Return any unused product to the pharmacy for a refund
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.